Neoneuron
Private Company
Total funding raised: $5.5M
Overview
Founded in 2018 and based in Boston, NeoNeuron is a private, pre-clinical stage biotech developing regenerative therapies for neurological disorders. The company's core expertise lies in purifying homogeneous neural stem cell lines and directing their differentiation to replace lost neurons, primarily targeting Parkinson's disease and ischemic stroke. Operating with a patient-centered approach, NeoNeuron advances its programs through internal R&D, strategic partnerships, and contract research services in validated animal models. The company is currently pre-revenue, focusing on translating its scientific platform into therapeutic candidates.
Technology Platform
Platform for purifying homogeneous neural stem cell lines and directing their differentiation into specific, functional neural cell types for brain repair.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
NeoNeuron competes in a crowded field including other cell therapy developers (e.g., BlueRock Therapeutics, Aspen Neuroscience), gene therapy companies, and large pharma with neurological pipelines. Differentiation hinges on demonstrating superior cell purity, survival, and functional integration in pre-clinical models.